Mizuho Updates Ests on Mallinckrodt (MNK) Amid EpiPen Headlines; Affirms at 'Buy'
Tweet Send to a Friend
Mizuho is updating estimates on Mallinckrodt (Nasdaq: MNK) following recent EpiPen news. The firm rates Mallinckrodt at Buy with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
